-
The Veterinary Record Mar 2009
Topics: Animals; Dog Diseases; Dogs; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Skin Neoplasms
PubMed: 19287036
DOI: 10.1136/vr.164.11.345-a -
The Veterinary Clinics of North... Jan 1996Making the most appropriate choices for diagnosis and treatment of canine and feline mast cell tumors remains challenging. An understanding of the heterogeneity of the... (Comparative Study)
Comparative Study Review
Making the most appropriate choices for diagnosis and treatment of canine and feline mast cell tumors remains challenging. An understanding of the heterogeneity of the disease process, the associated paraneoplastic disorders, and the known prognostic indicators can be helpful in making rational decisions regarding each individual case. A multimodality approach may be needed for optimal care of some patients, but the effectiveness of current medical treatment strategies continues to limit our ability to cure disseminated forms of disease.
Topics: Animals; Cat Diseases; Cats; Decision Making; Dog Diseases; Dogs; Mast-Cell Sarcoma; Prognosis
PubMed: 8825568
DOI: 10.1016/s0195-5616(96)50008-2 -
Modern Pathology : An Official Journal... Jul 1999Mast cell sarcoma is a rare disease. We report an unusual case of this neoplasm arising in the ascending colon of a 32-year-old Japanese woman who presented with...
Mast cell sarcoma is a rare disease. We report an unusual case of this neoplasm arising in the ascending colon of a 32-year-old Japanese woman who presented with abdominal pain. An ulcerating mass in the colon was resected, along with enlarged mesenteric lymph nodes. Two years after surgery, the neoplasm recurred as left cervical lymphadenopathy and an intra-abdominal mass. Despite predonine and radiation therapy, the disease progressed, and the patient died. The tumor cells had abundant fine granular or clear cytoplasm, and oval, lobulated, or indented nuclei. Numerous mature eosinophils were intermingled with the tumor cells. Immunohistologic studies on paraffin sections demonstrated that the majority of the tumor cells were strongly positive for CD45RB, CD68, and mast cell tryptase. They were unreactive, however, with a broad spectrum of antibodies against myelomonocytic and lymphocytic antigens. The mast cell nature of this rare type of tumor can be best identifiable by immunostains for mast cell tryptase.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chymases; Colon; Colonic Neoplasms; Eosinophilia; Female; Humans; Immunohistochemistry; Leukocyte Common Antigens; Mast-Cell Sarcoma; Serine Endopeptidases; Tryptases
PubMed: 10430280
DOI: No ID Found -
The American Journal of Surgical... Mar 2013Mast cell sarcoma (MCS) is an extremely rare neoplasm with a clinically aggressive course. Because of its rarity, its morphologic and molecular characteristics are still...
Mast cell sarcoma (MCS) is an extremely rare neoplasm with a clinically aggressive course. Because of its rarity, its morphologic and molecular characteristics are still not well defined. We report a case of a 15-year-old girl with MCS of the temporal bone extending into the posterior fossa creating a mass effect. The lesion mimicked a histiocytic neoplasm morphologically, but showed a novel KIT missense mutation, L799F (2395 C>T). The KIT D816V mutation is frequently found in systemic mastocytosis, but it has not been documented in the few reported human MCS cases. However, 1 reported case of MCS has shown a different alteration in the KIT gene. Our case is the first MCS case with L799F mutation, located between the catalytic loop (790 to 797) and the activation loop (810 to 837) of the KIT gene, and only the second case of MCS with KIT mutation documented in the literature. Proximity of the L799F mutation to the enzymatic region of the KIT tyrosine kinase domain may induce resistance to tyrosine kinase inhibitors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Diagnosis, Differential; Female; Histiocytic Sarcoma; Humans; Immunohistochemistry; Mast-Cell Sarcoma; Mutation, Missense; Proto-Oncogene Proteins c-kit; Radiotherapy; Temporal Bone
PubMed: 23388130
DOI: 10.1097/PAS.0b013e31828446d6 -
The Veterinary Record Jul 2012
Topics: Animals; Dog Diseases; Dogs; Male; Mast Cells; Mast-Cell Sarcoma; Muscle Neoplasms; Prognosis; Treatment Outcome
PubMed: 22843746
DOI: 10.1136/vr.e5024 -
Journal of Veterinary Diagnostic... Oct 1994Twelve histochemical methods; affinity staining with avidin peroxidase, wheat germ agglutinin, and concavalin-A agglutinin; and an immunohistochemical stain with Kp1... (Comparative Study)
Comparative Study
Twelve histochemical methods; affinity staining with avidin peroxidase, wheat germ agglutinin, and concavalin-A agglutinin; and an immunohistochemical stain with Kp1 (CD68) antibody were compared for their relative effectiveness in staining canine mast cell tumors. Stains were compared in 28 mast cell tumors and 19 histiocytomas. The effectiveness of the histochemical methods and the lectins decreased as the mast cells became less differentiated. None of the staining methods were positive on histiocytomas. Periodic acid-Schiff (PAS) gave positive results in a few cases of mast cell tumors where other histochemical stains were negative. Although avidin peroxidase and Kp1 antibody stained more mast cell tumors than any other method, they did not differ significantly from Luna's method, toluidine blue pH 0.5, toluidine blue pH 4.5, alcian blue pH 2.5, safranin O, Unna's method, and Giemsa. No stain was ideal for the diagnosis of canine mast cell tumors; however, this study suggests that the use of avidin peroxidase, Kp1 antibody, and PAS may give additional information for individual poorly differentiated tumors without substantial increase in time or cost.
Topics: Animals; Dog Diseases; Dogs; Histiocytoma, Benign Fibrous; Histocytochemistry; Immunohistochemistry; Mast-Cell Sarcoma; Staining and Labeling; Statistics as Topic
PubMed: 7532014
DOI: 10.1177/104063879400600410 -
Seminars in Veterinary Medicine and... Feb 1986Our understanding of the etiology, behavior, and most effective form of mast cell tumor treatment is rudimentary. I have tried to indicate specific areas that need... (Review)
Review
Our understanding of the etiology, behavior, and most effective form of mast cell tumor treatment is rudimentary. I have tried to indicate specific areas that need further study in order to resolve some of the present controversies. Clinicians should recognize that many of the published recommendations for treatment of mast cell tumors are based on opinion and should be viewed with skepticism. Because of the infrequence of this tumor in man, limited help can be expected from human oncologists, and thus the burden of responsibility for progress in predicting behavior and developing effective treatment for canine mast cell tumors falls on the shoulders of veterinarians.
Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Male; Mast-Cell Sarcoma
PubMed: 3148990
DOI: No ID Found -
The Journal of Small Animal Practice Mar 1997
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Diagnosis, Differential; Dog Diseases; Dogs; Drug Therapy, Combination; Mast-Cell Sarcoma; Prednisolone; Skin Neoplasms; Vincristine
PubMed: 9097238
DOI: No ID Found -
Veterinary Pathology Sep 2002Mast cell tumors (MCTs) of gastrointestinal origin that had been surgically removed from 39 dogs were examined to evaluate their pathologic features. Miniature breeds,...
Mast cell tumors (MCTs) of gastrointestinal origin that had been surgically removed from 39 dogs were examined to evaluate their pathologic features. Miniature breeds, especially Maltese, were most frequently affected. The average age of affected dogs was 9.7 +/- 2.6 years. No sex difference was apparent. The most frequently affected sites were in the upper digestive tract, and the prognosis was very poor. Grossly, the gastrointestinal wall was prominently thickened, and the lumen of the affected gut was usually narrowed. Microscopically, there was diffuse transmural invasion of round to pleomorphic tumor cells. Tumor cells had moderate to abundant cytoplasm, round to ovoid nuclei with scattered chromatin, and mitotic figures. Fibrous stroma was observed in about half of the tumors. There was variable infiltration of eosinophils. In all tumors, cytoplasmic granules showed weak metachromasia, but the number of granules was very small. Immunohistochemical staining for c-kit and mast cell tryptase was positive in 77% and 62% of tumors, respectively. All tumors were positive for at least two of these markers. Immunohistochemical staining for p53 was positive in 13% of the tumors. Reactivity for staining markers and p53 was unrelated to cell pleomorphism, vessel invasion, or survival time. Gastrointestinal MCTs have histologic and immunohistochemical features completely different from those of other primary or metastatic gastrointestinal tumors. The combination of immunostaining for mast cell tryptase and c-kit and histochemical staining for metachromasia appears to be a powerful tool for the diagnosis of gastrointestinal MCTs.
Topics: Animals; Dog Diseases; Dogs; Female; Gastrointestinal Neoplasms; Immunohistochemistry; Male; Mast Cells; Mast-Cell Sarcoma; Microscopy, Electron; Proto-Oncogene Proteins c-kit; Serine Endopeptidases; Tryptases; Tumor Suppressor Protein p53
PubMed: 12243465
DOI: 10.1354/vp.39-5-557 -
Journal of Pediatric Hematology/oncology Feb 2001Cerebral involvement of systemic mastocytosis and intracranial sarcoma of myelogenic origin are well known entities. An 8-year-old girl with an isolated cerebral mast...
Cerebral involvement of systemic mastocytosis and intracranial sarcoma of myelogenic origin are well known entities. An 8-year-old girl with an isolated cerebral mast cell tumor is presented. Specific histopathologic stains were used to confirm the diagnosis detecting immunophenotype and proliferative activity. Treatment with irradiation, intrathecal cytarabine, and interferon-alpha2b did not induce regression whereas polychemotherapy did. Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease Progression; Etoposide; Fatal Outcome; Female; Headache; Humans; Immunologic Factors; Injections, Spinal; Interferon alpha-2; Interferon-alpha; Mast-Cell Sarcoma; Nausea; Neoplasm Recurrence, Local; Palliative Care; Papilledema; Parietal Lobe; Prednisolone; Radioisotope Teletherapy; Recombinant Proteins; Remission Induction; Supratentorial Neoplasms; Temporal Lobe; Treatment Failure; Vomiting
PubMed: 11216707
DOI: 10.1097/00043426-200102000-00014